Gastrointestinal disease and the kidney

European Journal of Gastroenterology and Hepatology

Volumn 14, Issue SUPPL. 1, 2002, Pages

  De Francisco, Angel Luis Martin ^a  

^a HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

Author keywords

Acid related disease; Haemodialysis; Peritoneal dialysis; Proton pump inhibitor; Renal transplantation; Uraemia

Indexed keywords

ANTACID AGENT; ANTIBIOTIC AGENT; BETA 2 MICROGLOBULIN; CHOLECYSTOKININ; CIMETIDINE; CYCLOSPORIN; DIMETHYLARGININASE; GASTRIN; GUANIDINE DERIVATIVE; HIPPURIC ACID DERIVATIVE; HISTAMINE H2 RECEPTOR ANTAGONIST; HOMOCYSTEINE; IMMUNOSUPPRESSIVE AGENT; INDICAN; INDOLE DERIVATIVE; NEUROTENSIN; NITRIC OXIDE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PARATHYROID HORMONE; PEPTIDE; PHENOL DERIVATIVE; PHOSPHATE; POLYAMINE; PROTON PUMP INHIBITOR; PURINE DERIVATIVE; RABEPRAZOLE; TACROLIMUS; URATE; UREA;

ANALGESIC NEPHROPATHY; COMORBIDITY; CONFERENCE PAPER; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; CREATININE BLOOD LEVEL; DISEASE ASSOCIATION; DUODENUM ULCER; ERADICATION THERAPY; EROSIVE GASTRITIS; GASTROINTESTINAL DISEASE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HEMODIALYSIS; HUMAN; INTERSTITIAL NEPHRITIS; KIDNEY DISEASE; KIDNEY DYSFUNCTION; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; NEPHROTOXICITY; PRIORITY JOURNAL; RISK FACTOR; STOMACH ULCER;

GASTROINTESTINAL DISEASES; HUMANS; KIDNEY DISEASES; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; PERITONEAL DIALYSIS, CONTINUOUS AMBULATORY; RENAL DIALYSIS;

EID: 0036749664     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (50)

1. Sigel A, Botticher R, Wilhelm E. Urological complications in chronic inflammatory diseases of the bowel. Eur Urol 1977; 3:7-10.
2. Caudarella R, Rizzoli E, Pironi L, Malavolta N, Martelli G, Poggioli G, et al. Renal stone formation in patients with inflammatory bowel disease. Scanning Microsc 1993; 7:371-380.
3. Kreisel W, Wolf LM, Grotz W, Grieshaber M. Renal tubular damage: an extraintestinal manifestation of chronic inflammatory bowel disease. Eur J Gastroenterol Hepatol 1996; 8:461-468.
4. Akutsu Y, Itami N, Tanaka M, Kusunoki Y, Tochimaru H, Takekoshi Y. IgA nephritis in Behçet's disease: case report and review of the literature. Clin Nephrol 1990; 34:52-55.
5. Wagrowska-Danilewicz M, Danilewicz M. Glomerulonephritis associated with malignant diseases of nonrenal origin: a report of three cases and a review of the literature. Pol J Pathol 1995; 46:195-198.
6. Enriquez R, Sirvent AE, Cabezuelo JB, Pérez-Ramos M, Amorós F, Reyes A. Membranoproliferative glomerulonephritis and gastric adenocarcinoma. Nephrol Dial Transplant 1999; 14:242-243.
7. Dussol B, Berland Y, Casanova P. Crescentic glomerulonephritis associated with gastric adenocarcinoma. Nephrologie 1992; 13:163-165.
8. Waki M, Ishimura E, Morii H, Sakai S, Saitoh S, Kobayashi T, et al. A case of membranous glomerulonephritis associated with gastric cancer. Osaka City Med J 1997; 43:95-105.
9. Robson WL. Haemolytic uraemic syndrome. Paediatr Drugs 2000; 2:243-252.
10. Freston JW. Cimetidine, II: adverse reactions and patterns of use. Ann Intern Med 1982; 97:728-734.
11. Maton PN, Burton ME. Antacids revisited: a review of their clinical pharmacology and recommended therapeutic use. Drugs 1999; 57:855-870.
12. Hernandez-Diaz S, Garcia-Rodriguez LA. Epidemiologic assessment of the safety of conventional nonsteroidal anti-inflammatory drugs. Am J Med 2001; 110(3, Suppl. 1):20-27.
13. Fackovcova D, Kristova V, Kriska M. Renal damage induced by the treatment with nonopioid analgesics - theoretical assumption or clinical significance. Bratisl Lek Listy 2000; 101:417-422.
14. Elseviers MM, De Broe ME. Analgesic abuse in the elderly: renal sequelae and management. Drugs Aging 1998; 12:391-400.
15. Horn J. The proton pump inhibitors: similarities and differences. Clin Ther 2000; 22:266-280.
16. Lew EA. Review article: pharmacokinetic concerns in the selection of antiulcer therapy. Aliment Pharmacol Ther 1999; 13(Suppl. 5):11-16.
17. Gladziwa U, Klotz U. Pharmacokinetic optimisation of the treatment of peptic ulcer in patients with renal failure. Clin Pharmacokinet 1994; 27:393-408.
18. Keane WF, Swan SK, Grimes I, Humphries TJ. Rabeprazole: pharmacokinetics and tolerability in patients with stable, end-stage renal failure. J Clin Pharmacol 1999; 39:927-933.
19. d'Adamo G, Spinelli C, Forte F, Gangeri F. Omeprazole-induced acute interstitial nephritis. Renal Fail 1997; 19:171-175.
20. Post AT, Voorhorst G, Zanen AL. Reversible renal failure after treatment with omeprazole. Neth J Med 2000; 57:58-61.
21. Assouad M, Vicks SL, Pokroy MV, Willcourt RJ. Recurrent acute interstitial nephritis on rechallenge with omeprazole. Lancet 1994; 344:549.
22. Jones B, Hewson E, Price A. Acute interstitial nephritis due to omeprazole. Lancet 1994; 344:1017-1018.
23. Ala-Kaila K, Pasternack A. Gastrointestinal complications in chronic renal failure. Dig Dis 1989; 7:230-242.
24. Etemad B. Gastrointestinal complications of renal failure. Gastroenterol Clin North Am 1998; 27:875-892.
25. Ravelli AM. Gastrointestinal function in chronic renal failure. Pediatr Nephrol 1995; 9:756-762.
26. Prakash J, Agrawal BK. Upper gastrointestinal mucosal lesions in chronic renal failure. Indian J Gastroenterol 1991; 10:131-132.
27. Chalasani N, Cotsonis G, Wilcox CM. Upper gastrointestinal bleeding in patients with chronic renal failure: role of vascular ectasia. Am J Gastroenterol 1996; 91:2329-2332.
28. Margolis DM, Saylor JL, Geisse G, DeSchryver-Kecskemeti K, Harter HR, Zuckerman GR. Upper gastrointestinal disease in chronic renal failure: a prospective evaluation. Arch Intern Med 1978; 138:1214-1217.
29. Milito G, Taccone-Gallucci M, Brancaleone C, Nardi F, Filingeri V, Cesca D, et al. Assessment of the upper gastrointestinal tract in haemodialysis patients awaiting renal transplantation. Am J Gastroenterol 1983; 78:328-331.
30. Montemurro NE, Di Maggio A, Loperfido A, Franceschi M, Scatizzi A. Effects of omeprazole therapy on peptic disease and serum gastrin levels in haemodialysis patients: a preliminary study. Clin Nephrol 1993; 40:296-298.
31. Walker MM, Crabtree JE. Helicobacter pylori infection and the pathogenesis of duodenal ulceration. Ann NY Acad Sci 1998; 859:96-111.
32. Langtry HD, Markham A. Rabeprazole: a review of its use in acid-related gastrointestinal disorders. Drugs 1999; 58:725-742.
33. Tamura H, Tokushima H, Murakawa M, Matsumura O, Itoyama S, Sekine S, et al. Eradication of Helicobacter pylori in patients with end-stage renal disease under dialysis treatment. Am J Kidney Dis 1997; 29:86-90.
34. Muñoz de Bustillo E, Sánchez Tomero JA, Sanz JC, Moreno JA, Jiménez I, López-Brea M, et al. Eradication and follow-up of Helicobacter pylori infection in haemodialysis patients. Nephron 1998; 79:55-60.
35. Gokal R, Mallick NP. Peritoneal dialysis. Lancet 1999; 353:823-828.
36. Pollock CA, Ibels LS, Caterson RJ, Mahony JF, Waugh DA, Cocksedge B. Continuous ambulatory peritoneal dialysis: eight years of experience at a single center. Medicine 1989; 68:293-308.
37. Weigert AL, Schafer AI. Uraemic bleeding: pathogenesis and therapy. Am J Med Sci 1998; 316:94-104.
38. Kathuria P, Sakhuja V, Gupta KL, Jha V, Kochhar R, Joshi K, et al. Gastrointestinal complications after renal transplantation: 10-year data from a North Indian transplant center. ASAIO J 1995; 41:M698-M703.
39. Komorowski RA, Cohen EB, Kauffman HM, Adams MB. Gastrointestinal complications in renal transplant recipients. Am J Clin Pathol 1986; 86:161-167.
40. Teenan RP, Burgoyne M, Brown IL, Murray WR. Helicobacter pylori in renal transplant recipients. Transplantation 1993; 56:100-103.
41. Rossi SJ, Schroeder TJ, Hariharan S, First MR. Prevention and management of the adverse effects associated with immunosuppressive therapy. Drug Safety 1993; 9:104-131.
42. de Mattos AM, Olyaei AJ, Bennett WM. Nephrotoxicity of immunosuppressive drugs: long-term consequences and challenges for the future. Am J Kidney Dis 2000; 35:333-346.
43. Albengres E, Tillement JP. Cyclosporin and ketoconazole, drug interaction or therapeutic association? Int J Clin Pharmacol Ther Toxicol 1992; 30:555-570.
44. Skala I, Mareckova O, Vitko S, Matl I, Lacha J. Prophylaxis of acute gastro-duodenal bleeding after renal transplantation. Transplant Int 1997; 10:375-378.
45. 2-receptor antagonists on renal function in cyclosporine-treated renal transplant patients. Transplantation 1989; 47:254-259.
46. Lorf T, Ramadori G, Ringe B, Schwörer H. Pantoprazole does not affect cyclosporin A blood concentration in kidney-transplant patients. Eur J Clin Pharmacol 2000; 55:733-735.
47. Blohme I, Idstrom JP, Andersson T. A study of the interaction between omeprazole and cyclosporine in renal transplant patients. Br J Clin Pharmacol 1993; 35:156-160.
48. Matsuda H, Iwasaki K, Shiraga T, Tozuka Z, Hata T, Guengerich FP. Interactions of FK506 (tacrolimus) with clinically important drugs. Res Commun Mol Pathol Pharmacol 1996; 91:57-64.
49. Ishizaki T, Horai Y. Review article: cytochrome P450 and the metabolism of proton pump inhibitors - emphasis on rabeprazole. Aliment Pharmacol Ther 1999; 13(Suppl. 3):27-36.
50. Humphries TJ, Merritt GJ. Review article: drug interactions with agents used to treat acid-related diseases. Aliment Pharmacol Ther 1999; 13(Suppl. 3):18-26.